332941-25-0 Usage
Description
O,O′-Bis(2-aMinoethyl)polyethylene Glycol, also known as Amino-PEG7-Amine, is a polyethylene glycol (PEG) derivative that serves as a crosslinking reagent with two amino groups. These amino (NH2) groups are highly reactive, allowing them to interact with various functional groups such as carboxylic acids, activated NHS esters, and carbonyls (ketone, aldehyde). This unique property makes it a versatile compound with potential applications in various industries.
Uses
Used in Biochemical Research:
O,O′-Bis(2-aMinoethyl)polyethylene Glycol is used as a reagent for the preparation of biotinylated spacers present in glucose-transporter probes. Its ability to form stable covalent bonds with different functional groups makes it an essential component in the development of these probes, which are crucial for studying glucose transport mechanisms in cells.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, O,O′-Bis(2-aMinoethyl)polyethylene Glycol is used as a key component in the synthesis of drug conjugates and targeted drug delivery systems. Its reactive amino groups facilitate the attachment of therapeutic molecules to carriers, such as nanoparticles or antibodies, enhancing the specificity and efficacy of drug delivery.
Used in Material Science:
O,O′-Bis(2-aMinoethyl)polyethylene Glycol is used as a building block for the development of novel biocompatible materials. Its reactive amino groups can be utilized to create crosslinked networks or copolymers with tailored properties, such as hydrogels for tissue engineering or drug release systems.
Used in Diagnostics:
O,O′-Bis(2-aMinoethyl)polyethylene Glycol is used as a component in the development of diagnostic tools, such as immunoassays and biosensors. Its ability to form stable bonds with various biomolecules allows for the creation of highly specific and sensitive detection systems.
Check Digit Verification of cas no
The CAS Registry Mumber 332941-25-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,2,9,4 and 1 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 332941-25:
(8*3)+(7*3)+(6*2)+(5*9)+(4*4)+(3*1)+(2*2)+(1*5)=130
130 % 10 = 0
So 332941-25-0 is a valid CAS Registry Number.
332941-25-0Relevant articles and documents
Synthesis and stability of novel terminal phosphate-labeled nucleotides
Reynolds, Bambi,Miller, Rachel,Williams, John G.,Anderson, Jon P.
, p. 18 - 30 (2008)
Novel compounds consisting of a nucleotide triphosphate labeled with a PEG linker and various terminal groups attached to the γ-phosphate of the nucleotide were constructed for use in efforts to produce a new class of DNA sequencer. The stability of these novel compounds was investigated to determine their utility as sequencing reagents. Hydrolysis rate constants were measured for both the natural nucleoside triphosphate dATP and novel dATP derivatives. The γ-labeled dATP was approximately 20-fold more stable to hydrolysis than dATP. Copyright Taylor & Francis Group, LLC.
Bivalent HIV-1 fusion inhibitors based on peptidomimetics
Kobayakawa, Takuya,Ebihara, Kento,Tsuji, Kohei,Kawada, Takuma,Fujino, Masayuki,Honda, Yuzuna,Ohashi, Nami,Murakami, Tsutomu,Tamamura, Hirokazu
, (2020/11/07)
Membrane fusion is a valid target for inhibition of HIV-1 replication. A 34-mer fragment peptide (C34), which is contained in the HIV-1 envelope protein gp41, has significant anti-HIV activity. Previously, a dimeric derivative of C34 linked by a disulfide bridge at its C-terminus was found to have more potent anti-HIV activity than the C34 peptide monomer. To date, several peptidomimetic small inhibitors have been reported, but most have lower potency than peptide derivatives related to C34. In the present study we applied this dimerization concept to these peptidomimetic small inhibitors and designed several bivalent peptidomimetic HIV-1 fusion inhibitors. The importance of the length of linkers crosslinking two peptidomimetic compounds was demonstrated and several potent bivalent inhibitors containing tethered peptidomimetics were produced.
